Publications scientifiques en 2021

Depuis le 30/04/2024

  1. Patterns of Benzodiazepine Use and Excess Risk of All-Cause Mortality in the Elderly: A Nationwide Cohort Study.
    Mathieu C, Joly P, Jacqmin-Gadda H, Wanneveich M, Bégaud B, Pariente A.
    Drug Saf. 2021
  2. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
    Meriglier E, Rivoisy C, Hessamfar M, Bernard N, Aureau I, Lapoirie J, Contis A, Sacher F, Sacristan B, Lahouati M, Pedeboscq S, Vandenhende MA, Bouchet S, Bonnet F.
    J Antimicrob Chemother. 2021
  3. Hair Analysis of Methoxphenidine in a Forensic Chemsex Case.
    Goncalves R, Castaing N, Titier K, Dumestre-Toulet V.
    J Anal Toxicol. 2021
  4. Neglecting plasma protein binding in COVID-19 patients leads to a wrong interpretation of lopinavir overexposure.
    Stanke-Labesque F, Concordet D, Djerada Z, Bouchet S, Solas C, Mériglier E, Bonnet F, Mourvillier B, Ruiz S, Martin-Blondel G, Epaulard O, Schwebel C, Gautier-Veyret E, Gandia P.
    Clin Pharmacol Ther. 2021
  5. Anticholinergic Activity of Psychotropic Drugs and Cognitive Impairment Among Participants Aged 45 and Over: The CONSTANCES Study .
    Ziad A, Berr C, Ruiz F, Bégaud B, Lemogne C, Goldberg M, Zins M, Mura T.
    Drug Saf. 2021
  6. Decongestant use and the risk of myocardial infarction and stroke: a case-crossover study.
    Grimaldi-Bensouda L, Bégaud B, Benichou J, Nordon C, Dialla O, Morisot N, Hamon Y, Cottin Y, Serrano E, Abenhaim L, Touzé E.
    Sci Rep. 2021
  7. Added Therapeutic Value of Medicinal Products for French and German Health Technology Assessment Organizations: A Systematic Comparison.
    Boucaud-Maitre D, Berdaï D, Salvo F.
    Value Health. 2021
  8. A safety signal of somnambulism with the use of antipsychotics and lithium: a pharmacovigilance disproportionality analysis.
    Gouverneur A, Ferreira A, Morival C, Pageot C, Tournier M, Pariente A.
    Br J Clin Pharmacol. 2021
  9. Cost-effectiveness of screening of coronary artery disease in patients with type 2 DIABetes at a very high cardiovascular risk (SCADIAB study) rational and design.
    Mohammedi K, Préaubert N, Cariou T, Rigalleau V, Foussard N, Piazza L, Bairras-Martin C, Couffinhal T, Bezin J, Benard A.
    Cardiovasc Diabetol. 2021
  10. Association Between Antiangiogenic Drugs Used for Cancer Treatment and Artery Dissections or Aneurysms.
    Guyon J, Gouverneur A, Maumus-Robert S, Bérard X, Pariente A, Bikfalvi A, Noize P.
    JAMA Oncol. 2021
  11. Mapping of drug-related problems among older adults conciliating medical and pharmaceutical approaches.
    Laroche ML, Van Ngo TH, Sirois C, Daveluy A, Guillaumin M, Valnet-Rabier MB, Grau M, Roux B, Merle L.
    Eur Geriatr Med. 2021
  12. Performance Characteristics of Breezhaler® and Aerolizer® in the Real-World Setting.
    Molimard M, Kottakis I, Jauernig J, Lederhilger S, Nikolaev I.
    Clin Drug Investig. 2021
  13. Spontaneous Reports of Serious Adverse Drug Reactions Resulting From Drug-Drug Interactions: An Analysis From the French Pharmacovigilance Database.
    Létinier L, Ferreira A, Marceron A, Babin M, Micallef J, Miremont-Salamé G, Pariente A; French Network of Pharmacovigilance Centres.
    Front Pharmacol. 2021
  14. Cardiovascular Adverse Events With Intravitreal Anti-Vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
    Ngo Ntjam N, Thulliez M, Paintaud G, Salvo F, Angoulvant D, Pisella PJ, Bejan-Angoulvant T.
    JAMA Ophthalmol. 2021
  15. Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy.
    Soeiro T, Salvo F, Pariente A, Grandvuillemin A, Jonville-Béra AP, Micallef J.
    Therapie. 2021
  16. Artificial intelligence for unstructured healthcare data: application to coding of patient reporting of adverse drug reactions.
    Létinier L, Jouganous J, Benkebil M, Bel-Létoile A, Goehrs C, Singier A, Rouby F, Lacroix C, Miremont G, Micallef J, Salvo F, Pariente A.
    Clin Pharmacol Ther. 2021
  17. [Allergic Broncho-Pulmonary Aspergillosis (ABPA) in cystic fibrosis: Mechanisms, diagnosis and therapeutic options]
    Bui S, Dournes G, Fayon M, Bouchet S, Burgel PR, Macey J, Murris M, Delhaes L.
    Rev Mal Respir. 2021
  18. Nurses' internal contamination by antineoplastic drugs in hospital centers: a cross-sectional descriptive study.
    Villa A, Molimard M, Sakr D, Lassalle R, Bignon E, Martinez B, Rouyer M, Mathoulin-Pelissier S, Baldi I, Verdun-Esquer C, Canal-Raffin M.
    Int Arch Occup Environ Health. 2021
  19. Assessment of workplace environmental contamination and occupational exposure to cisplatin and doxorubicin aerosols during electrostatic pressurized intraperitoneal aerosol chemotherapy.
    Roussin F, Taibi A, Canal-Raffin M, Cantournet L, Durand-Fontanier S, Druet-Cabanac M, El Balkhi S, Maillan G.
    Eur J Surg Oncol. 2021
  20. Ambulatory drug changes in the elderly after hospital discharge: A cohort study.
    Rousselot N, Joseph JP, Noïze P, Berdaï D, Fourrier-Réglat A, Bosco-Levy P.
    Therapie. 2021
  21. Evaluation of bronchial wall thickness in asthma using magnetic resonance imaging.
    Benlala I, Dournes G, Girodet PO, Benkert T, Laurent F, Berger P.
    Eur Respir J. 2021
  22. French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge.
    Lacroix C, Salvo F, Gras-Champel V, Gautier S, Massy N, Valnet-Rabier MB, Grandvuillemin A, Mounier C, Benkebil M, Pariente A, Jonville-Bera AP, Micallef J; French Network of Pharmacovigilance Centres.
    Therapie. 2021
  23. Atypical thrombosis associated with VaxZevria® (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres.
    Gras-Champel V, Liabeuf S, Baud M, Albucher JF, Benkebil M, Boulay C, Bron A, El Kaddissi A, Gautier S, Geeraerts T, Girot M, Grandvuillemin A, Laujin H, Jonville-Bera AP, Masmoudi K, Massardier E, Micallef J, Mounier C, Montastruc F, Pariente A, Perez J, Raposo N, Salvo F, Valnet-Rabier MB, Vial T, Massy N; French Network of Pharmacovigilance Centres.
    Therapie. 2021
  24. REview of potentially inappropriate MEDIcation pr[e]scribing in Seniors (REMEDI[e]S): French implicit and explicit criteria.
    Roux B, Berthou-Contreras J, Beuscart JB, Charenton-Blavignac M, Doucet J, Fournier JP, de la Gastine B, Gautier S, Gonthier R, Gras V, Grau M, Noize P, Polard E, Rudelle K, Valnet-Rabier MB, Tannou T, Laroche ML.
    Eur J Clin Pharmacol. 2021
  25. COVID-19: Pharmacology has kept the science ship running during the storm.
    Molimard M, Richard V, Cracowski JL.
    Therapie. 2021
  26. Evaluation of Covid-19 vaccines: Pharmacoepidemiological aspects.
    Pariente A, Bezin J.
    Therapie. 2021
  27. Leveraging the Variability of Pharmacovigilance Disproportionality Analyses to Improve Signal Detection Performances.
    Khouri C, Nguyen T, Revol B, Lepelley M, Pariente A, Roustit M, Cracowski JL.
    Front Pharmacol. 2021
  28. ADL-dependent older adults were identified in medico-administrative databases.
    Hucteau E, Noize P, Pariente A, Helmer C, Pérès K.
    J Clin Epidemiol. 2021
  29. High prevalence of spin was found in pharmacovigilance studies usingdisproportionality analyses todetectsafetysignals: a meta-epidemiologicalstudy: Spin in pharmacovigilance disproportionality analyses.
    Mouffak A, Lepelley M, Revol B, Bernardeau C, Salvo F, Pariente A, Roustit M, Cracowski JL, Khouri C.
    J Clin Epidemiol. 2021
  30. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
    Rousselot P, Mollica L, Guilhot J, Guerci A, Nicolini FE, Etienne G, Legros L, Charbonnier A, Coiteux V, Dartigeas C, Escoffre-Barbe M, Roy L, Cony-Makhoul P, Dubruille V, Gardembas M, Huguet F, Réa D, Cayssials E, Guilhot F, Bergeron A, Molimard M, Mahon FX, Cayuela JM, Busque L, Bouchet S.
    Br J Haematol. 2021
  31. Targeting of under-75 years for the optimization of medication reconciliation with an approach based on medication risks: An observational study.
    Perino J, Gouverneur A, Bonnet F, Lahouati M, Bernard N, Breilh D, Pariente A, Xuereb F.
    Therapie. 2021
  32. Real-World Utilization of Target- and Immunotherapies for Lung Cancer: A Scoping Review of Studies Based on Routinely Collected Electronic Healthcare Data.
    Spini A, Hyeraci G, Bartolini C, Donnini S, Rosellini P, Gini R, Ziche M, Salvo F, Roberto G.
    Int J Environ Res Public Health. 2021
  33. A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases.
    Khouri C, Revol B, Lepelley M, Mouffak A, Bernardeau C, Salvo F, Pariente A, Roustit M, Cracowski JL.
    J Clin Epidemiol. 2021
  34. Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality Analysis.
    Gouverneur A, Sanchez-Pena P, Veyrac G, Salem JE, Bégaud B, Bezin J.
    Cardiovasc Drugs Ther. 2021
  35. Specific features of amoxicillin-associated DRESS: a nationwide study.
    Largeau B, Agier MS, Beau-Salinas F, Pariente A, Maruani A, Vial T, Jonville-Béra AP.
    J Eur Acad Dermatol Venereol. 2021
  36. Chronic polypharmacy at all age: a population-based drug utilization study.
    Guillot J, Maumus-Robert S, Pariente A, Bezin J.
    Fundam Clin Pharmacol. 2021
  37. Human Papillomavirus Vaccination and Premature Ovarian Failure: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System.
    Tatang C, Arredondo Bisonó T, Bergamasco A, Salvo F, Costa Clemens SA, Moride Y.
    Drugs Real World Outcomes. 2021
  38. Prevalence and direct costs of potentially inappropriate prescriptions in France: a population-based study.
    Roux B, Bezin J, Morival C, Noize P, Laroche ML.
    Expert Rev Pharmacoecon Outcomes Res. 2021
  39. Systematising Pharmacovigilance Engagement of Patients, Healthcare Professionals and Regulators: A Practical Decision Guide Derived from the International Risk Governance Framework for Engagement Events and Discourse.
    Bahri P, Pariente A.
    Drug Saf. 2021
  40. Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study.
    Just J, Thonnelier C, Bourgoin-Heck M, Mala L, Molimard M, Humbert M; STELLAIR Investigators.
    J Asthma Allergy. 2021
  41. General practitioners' compliance with benzodiazepine discontinuation guidelines in patients treated with long-term lorazepam: A case-vignette cross-sectional survey.
    Singier A, Carrier H, Tournier M, Pariente A, Verger P, Salvo F.
    Therapie. 2021
  42. The risk of dementia in patients using psychotropic drugs: antidepressants, mood stabilizers or antipsychotics.
    Tournier M, Pambrun E, Maumus-Robert S, Pariente A, Verdoux H.
    Acta Psychiatr Scand. 2021
  43. Adverse drug reactions induced by cotrimoxazole: still a lot of preventable harm.
    Coppry M, Duret S, Berdaï D, Miremont-Salamé G, Fourrier-Réglat A, Haramburu F, Rogues AM, Noize P.
    Fundam Clin Pharmacol. 2021
  44. A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019).
    Perri-Plandé J, Miremont-Salamé G, Micallef J, Herman C, Baumevieille M, Abriat F, Lapeyre-Mestre M, Haramburu F, Daveluy A; French Addictovigilance Network.
    Drug Saf. 2021
  45. Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database.
    Allouchery M, Tomowiak C, Lombard T, Pérault-Pochat MC, Salvo F.
    Front Pharmacol. 2021
  46. Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines.
    Foltran D, Delmas C, Flumian C, De Paoli P, Salvo F, Gautier S, Drici MD, Karsenty C, Montastruc F.
    Eur Heart J Qual Care Clin Outcomes. 2021
  47. Involuntary MDMB-4en-PINACA intoxications following cannabis consumption: clinical and analytical findings.
    Goncalves R, Labadie M, Chouraqui S, Peyré A, Castaing N, Daveluy A, Molimard M.
    Clin Toxicol (Phila). 2021
  48. Features of inflammatory heart reactions following mRNA COVID-19 vaccination at a global level.
    Chouchana L, Blet A, Al-Khalaf M, Kafil TS, Nair G, Robblee J, Drici MD, Valnet-Rabier MB, Micallef J, Salvo F, Treluyer JM, Liu PP.
    Clin Pharmacol Ther. 2021
  49. [Introduction of an anticholinesterase drug in the context of myasthenia, in a severe asthmatic patient]
    Ghrenassia G, Grassion L, Molimard M, Sanchez-Pena P, Raherison C.
    Rev Mal Respir. 2021
  50. First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective.
    Spini A, Gini R, Rosellini P, Singier A, Bellan C, Pascucci A, Leoncini L, Mathieu C, Martellucci I, Furiesi F, Giorgi S, Donnini S, Roberto G, Ziche M, Salvo F.
    Cancers (Basel). 2021
  51. Clinical pharmacology: Current innovations and future challenges.
    Cracowski JL, Hulot JS, Laporte S, Charvériat M, Roustit M, Deplanque D, Girodet PO; French Society of Pharmacology and Therapeutics (SFPT).
    Fundam Clin Pharmacol. 2021
  52. Pharmacoepidemiology for oncology clinical practice: Foundations, state of the art and perspectives.
    de Germay S, Berdaï D, Noize P.
    Therapie. 2021
  53. Pharmacokinetics and therapeutic drug monitoring of anticancer protein/kinase inhibitors.
    Bouchet S, Molimard M.
    Therapie. 2021